279 related articles for article (PubMed ID: 20002851)
1. The Bosentan Patient Registry: long-term survival in pulmonary arterial hypertension.
Keogh A; Strange G; McNeil K; Williams TJ; Gabbay E; Proudman S; Weintraub RG; Wlodarczyk J; Dalton B
Intern Med J; 2011 Mar; 41(3):227-34. PubMed ID: 20002851
[TBL] [Abstract][Full Text] [Related]
2. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan.
McLaughlin VV
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():10-5. PubMed ID: 16919005
[TBL] [Abstract][Full Text] [Related]
3. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
Denton CP; Humbert M; Rubin L; Black CM
Ann Rheum Dis; 2006 Oct; 65(10):1336-40. PubMed ID: 16793845
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.
Launay D; Sitbon O; Le Pavec J; Savale L; Tchérakian C; Yaïci A; Achouh L; Parent F; Jais X; Simonneau G; Humbert M
Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974
[TBL] [Abstract][Full Text] [Related]
5. Funding linked to ongoing research: impact of the bosentan patient registry on pricing in Australia.
Wlodarczyk J; Reid CM; Pater G
Value Health; 2011; 14(6):961-3. PubMed ID: 21914519
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes in pulmonary arterial hypertension in the first-line epoprostenol or first-line bosentan era.
Jacobs W; Boonstra A; Brand M; Rosenberg DM; Schaaf B; Postmus PE; Vonk Noordegraaf A
J Heart Lung Transplant; 2010 Oct; 29(10):1150-8. PubMed ID: 20580264
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension.
Provencher S; Sitbon O; Humbert M; Cabrol S; Jaïs X; Simonneau G
Eur Heart J; 2006 Mar; 27(5):589-95. PubMed ID: 16431875
[TBL] [Abstract][Full Text] [Related]
8. Bosentan improves skin perfusion of hands in patients with systemic sclerosis with pulmonary arterial hypertension.
Rosato E; Molinaro I; Borghese F; Rossi C; Pisarri S; Salsano F
J Rheumatol; 2010 Dec; 37(12):2531-9. PubMed ID: 20810512
[TBL] [Abstract][Full Text] [Related]
9. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.
Mathai SC; Girgis RE; Fisher MR; Champion HC; Housten-Harris T; Zaiman A; Hassoun PM
Eur Respir J; 2007 Mar; 29(3):469-75. PubMed ID: 17079256
[TBL] [Abstract][Full Text] [Related]
10. Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients.
Simonneau G; Galiè N; Jansa P; Meyer GM; Al-Hiti H; Kusic-Pajic A; Lemarié JC; Hoeper MM; Rubin LJ
Int J Cardiol; 2014 Mar; 172(2):332-9. PubMed ID: 24525158
[TBL] [Abstract][Full Text] [Related]
11. Survival of patients with idiopathic pulmonary arterial hypertension after listing for transplantation: impact of iloprost and bosentan treatment.
Dandel M; Lehmkuhl HB; Mulahasanovic S; Weng Y; Kemper D; Grauhan O; Knosalla C; Hetzer R
J Heart Lung Transplant; 2007 Sep; 26(9):898-906. PubMed ID: 17845928
[TBL] [Abstract][Full Text] [Related]
12. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol.
Sitbon O; McLaughlin VV; Badesch DB; Barst RJ; Black C; Galiè N; Humbert M; Rainisio M; Rubin LJ; Simonneau G
Thorax; 2005 Dec; 60(12):1025-30. PubMed ID: 16055621
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome and effects of oral bosentan therapy in Taiwanese patients with advanced idiopathic pulmonary arterial hypertension.
Hsu HH; Chen JS; Chen RJ; Ko WJ; Kuo SW; Wu ET; Wu MH; Wang JK; Lee YC
Respir Med; 2007 Jul; 101(7):1556-62. PubMed ID: 17223329
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases.
Girgis RE; Mathai SC; Krishnan JA; Wigley FM; Hassoun PM
J Heart Lung Transplant; 2005 Oct; 24(10):1626-31. PubMed ID: 16210140
[TBL] [Abstract][Full Text] [Related]
15. Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL).
Preston IR; Roberts KE; Miller DP; Sen GP; Selej M; Benton WW; Hill NS; Farber HW
Circulation; 2015 Dec; 132(25):2403-11. PubMed ID: 26510696
[TBL] [Abstract][Full Text] [Related]
16. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist?
van Loon RL; Hoendermis ES; Duffels MG; Vonk-Noordegraaf A; Mulder BJ; Hillege HL; Berger RM
Am Heart J; 2007 Oct; 154(4):776-82. PubMed ID: 17893008
[TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness of bosentan in the United Kingdom for patients with pulmonary arterial hypertension of WHO functional class III.
Stevenson MD; Macdonald FC; Langley J; Hunsche E; Akehurst R
Value Health; 2009; 12(8):1100-5. PubMed ID: 19558373
[TBL] [Abstract][Full Text] [Related]
18. The effect of bosentan on matrix metalloproteinase-9 levels in patients with systemic sclerosis-induced pulmonary hypertension.
Giannelli G; Iannone F; Marinosci F; Lapadula G; Antonaci S
Curr Med Res Opin; 2005 Mar; 21(3):327-32. PubMed ID: 15811199
[TBL] [Abstract][Full Text] [Related]
19. The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH.
Clements PJ; Tan M; McLaughlin VV; Oudiz RJ; Tapson VF; Channick RN; Rubin LJ; Langer A;
Ann Rheum Dis; 2012 Feb; 71(2):249-52. PubMed ID: 21998119
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, safety and tolerability of bosentan in Chinese patients with pulmonary arterial hypertension.
Jing ZC; Strange G; Zhu XY; Zhou DX; Shen JY; Gu H; Yang ZK; Pan X; Xiang MX; Yao H; Zhao DB; Dalton BS; Zhang ZL; Wang Y; Cheng XS; Yang YJ
J Heart Lung Transplant; 2010 Feb; 29(2):150-6. PubMed ID: 20113907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
